



ABS

ASSOCIATION OF
BREAST SURGERY



Association of Breast Surgery Conference and AGM

16th & 17th May 2011

Manchester Central Convention Complex



Final Programme

Welcome from the President



A very warm welcome to this year's Association of Breast Surgery Conference and AGM, and to our new venue at Manchester Central. Once again, Mark Sibbering and the organising committee have assembled a superb programme. This promises to bring delegates right up to speed with key developments which will have the biggest impact on our patients and our practice.

The programme has something for everyone. Three sessions address wide-ranging controversies and developments in surgery – including the ever-contentious management of the axilla, training, education and audit of the new cohort of oncoplastic surgeons, and an interactive video-based session exploring important technical aspects of new surgical procedures. We are honoured to include international contributions to these and other sessions including those from Professor Monica Morrow of the Memorial Sloan-Kettering Cancer Centre, New York, USA who will give the BJS lecture, and from Mr Jim Kollias of the Royal Adelaide Hospital, Adelaide, Australia, who will give the EJSO lecture.

Data collection and audit are integral to service improvement and Mrs Di Riley will explain the increasing role of the National Cancer Intelligence Network in the development, coordination and implementation of new national breast cancer datasets. This topic links with two interactive audit sessions addressing outliers in surgery and presenting data from the latest All Breast Cancer Report. Service improvement also depends on new trials and new treatments, which demand new decisions. These linked topics will be debated during two sessions – one which addresses new research developments and another which explores decision-making tools. This is the first time that submitted abstracts are being presented at this conference and I am sure that the BJS prize and poster sessions will attract widespread interest, particularly amongst trainees. Trainees will also enjoy this year's Mammary Fold symposium, which covers topics as diverse as trials, transfer of fat and training – with Mr Jim Kollias explaining some of the issues faced by trainees 'down under'.

Finally I am delighted to say that for the first time the ABS is hosting its Nursing Conference within this conference and it will run in parallel with the main programme on the first day. Key topics which impact on current practice have been chosen, including molecular targeting, a debate around the pros and cons of 23 hour surgery, decision making in breast cancer and managing life after diagnosis. Thank you very much for joining us in Manchester, and we are looking forward to a very enjoyable and stimulating event. Please let me know if you have ideas about key topics for next year's conference in Bournemouth.

A handwritten signature in black ink, which appears to read 'Dick Rainsbury'. The signature is fluid and cursive, written in a professional style.

Dick Rainsbury
President of the ABS



ASSOCIATION OF
BREAST SURGERY

Programme

Monday 16th May 2011

Exchange Auditorium

09:00 to 09:05

Welcome and Introductory Remarks

Mr Mark Sibbering, ABS Meetings Secretary
Mr Dick Rainsbury, ABS President

09:05 to 10:30

Session 1

BJS Prize Papers

Chairs:

Mr Dick Rainsbury & Mr Mark Sibbering

09:05 to 09:15

1. Acellular dermal matrix in immediate implant based breast reconstruction – a single surgeon’s experience

Mr Reza Alamouti, St Thomas’ Hospital, London

09:15 to 09:25

2. A pilot study to validate an objective structured assessment of technical skill tool for latissimus dorsi breast reconstruction

Mr Maisam Fazel, Imperial College Hospitals, London

09:25 to 09:35

3. First European experience of skin sparing mastectomy and immediate reconstruction using acellular dermal matrix Strattice and implant

Miss Claire Murphy,
Bradford Teaching Hospitals Foundation Trust

09:35 to 09:45

4. Intra-operative assessment of sentinel lymph nodes in breast cancer with touch implant cytology in 460 consecutive patients

Mrs Geeta Shetty, Warwick Hospital

Charter 3 - 5

ABS ABS Nursing
ASSOCIATION OF BREAST SURGERY **Conference**

09:55 to 10:00

Welcome

Mr Kieran Horgan, ABS Vice President

10:00 to 11:00

Session 2

New Developments: Molecular Targeting of Breast Cancer

Chair: *Mr Kieran Horgan*

10:00 to 10:20

Understanding molecular targeting and receptors

Dr Rahul Deb, Royal Derby Hospital

10:20 to 10:40

Molecular targeting of breast cancer: Current treatment and trials

Prof Nigel Bundred,
South Manchester University Hospital

10:40 to 11:00

What is in the pipeline?

Dr Liz Hamilton,
Senior Medical Manager, Roche Products Ltd

continued...

Exchange Auditorium

09:45 to 09:55

5. A comparison of nodal positivity between 'One Step Nucleic Acid Amplification' (OSNA) and routine pathology of sentinel lymph nodes

Miss Vivien Ng, Wycombe General Hospital/
Buckingham Healthcare NHS Trust

09:55 to 10:05

6. Is completion axillary lymph node dissection necessary for micrometastases?

Miss Wen-Chan Yeow, Royal Marsden NHS
Foundation Trust

10:05 to 10:15

7. Local oestrogen production can influence mammographic density in postmenopausal women

Mr Kelvin Chong, St George's Hospital, London

10:15 to 10:25

8. D-dimer as a biomarker in early breast cancer

Mr Hudhaifah Shaker,
University of South Manchester

10:30 to 11:00 Tea & Coffee Break

11:00 to 12:30

Session 3

Management of the Axilla

Chair: *Prof Michael Kerin*

11:00 to 11:30

Current practice

Dr Gill Lawrence, West Midlands Cancer Intelligence
Unit & *Mr Mark Sibbering*, Royal Derby Hospital

11:30 to 11:45

DCIS: Are we over treating the axilla? Results
from the NHSBSP Audit and the Sloane Project

Mr Stewart Nicholson, York Teaching Hospital

11:45 to 12:15

Sentinel Node Biopsy: The current evidence

Prof Monica Morrow, Memorial Sloan-Kettering
Cancer Centre, New York, USA

12:15 to 12:30

Discussion

Charter 3 - 5

New Developments continued...

11:00 to 11:30 Tea & Coffee Break

11:30 to 12:30

Session 4

Debate:

**23 hour discharge of breast cancer patients is a
significant improvement in patient care**

Chair: *Mr Chris Holcombe*

FOR:

Miss Geraldine Mitchell,

Royal Liverpool University Hospital

Mrs Veronica Rogers, Royal Derby Hospital

AGAINST:

Mr Ashu Gandhi,

South Manchester University Hospital

Ms Julie Orford,

South Manchester University Hospital

*There will be a short introduction by the Chair,
followed by a pre-debate vote on the motion. Each
proposer and seconder will then speak for 8 minutes.
This will be followed by 15 minutes discussion and a
final vote on the motion*

continued...

Monday 16th May 2011 continued

Exchange Auditorium

12:30 to 13:15
Association of Breast Surgery AGM
(open to ABS Members only)

Charter 3 - 5

12:30 to 14:00 Lunch

14:00 to 14:30
Session 5

European Journal of Surgical Oncology Lecture
Chair: *Mr Dick Rainsbury*

Breast Cancer Surgery in Australia and New Zealand
Mr James Kollias, Royal Adelaide Hospital, Australia

14:30 to 15:30
Session 7

Breast Cancer Audits: Outliers in surgery
Chair: *Mr Neil Rothnie*

Interactive audit session

Contributors:
Dr Gill Lawrence,
West Midlands Cancer Intelligence Unit
Mr Jim Kollias,
Royal Adelaide Hospital, Australia

14:00 to 15:30
Session 6

BRESDEX
Chair: *Prof Malcolm Reed*

14:00 to 14:10
The background to Bresdex
Ms Lisa Caldon
University of Sheffield

14:10 to 14:25
What is BresDex?
Mrs Veronica Rogers,
Royal Derby Hospital

14:25 to 14:40
How did we do it? Design & Development of BresDex
Ms Stephanie Sivell
Marie Curie Palliative Care Research Centre, WCTU, Cardiff

14:40 to 14:50
Patient experience of being faced with the decision and using BresDex
Mrs Eleri Hurt

14:50 to 15:10
The impact of BresDex
Ms Stephanie Sivell
Marie Curie Palliative Care Research Centre, WCTU, Cardiff

15:10 to 15:30
Demonstration of BresDex and discussion.

15:30 to 16:00 Tea & Coffee Break

continued...

Exchange Auditorium

16:00 to 17:30
Session 8

**Surgical Technique:
Operative Video Interactive Case Discussions**

Contributors:

*Mr John Scott, Glasgow Royal Infirmary
Mr Lee Martin, Aintree University Hospital
Mrs Katie Hogben, Charing Cross Hospital*

Charter 3 - 5

16:00 to 17:30
Session 9

Managing Survivorship

Chair: *Mrs Sue Holcombe*

16:00 to 16:15

Breast Care Nurse Follow up

*Ms Lesley Thomson,
South Manchester University Hospital*

16:15 to 16:30

Normalising Life after Breast Cancer

*Miss Samantha Ingham,
Royal Liverpool University Hospital*

16:30 to 16:45

Preparing for and continuing after surgery

*Ms Karen Livingstone
University Hospital of South Manchester*

16:45 to 17:00

Addressing and working with relational issues

*Ms Anne Cawthorn,
Blythe House, Chapel-en-le-Frith*

17:00 to 17:15

Patient Perspective

Ms Maureen Burton

17:15 to 17:30

Discussion

Charter 3 - 5

17:30 to 18:00

Mammary Fold AGM

Charter 6, 7 and 8

17:30 to 18:30

Poster Viewing and Drinks Reception

Exchange Auditorium

09:00 to 10:00
Session 10

Decision Making Tools

Chair: *Miss Fiona MacNeill*

09:00 to 09:20

BRESDEx

Prof Malcolm Reed, University of Sheffield

09:20 to 09:40

PREDICT

Prof Gordon Wishart,
Addenbrooke's Hospital, Cambridge

09:40 to 10:00

Prediction of chemotherapy response based on genomic information

Dr Sabine Linn,
The Netherlands Cancer Institute, Amsterdam

10:00 to 11:30
Session 12

Oncoplastic Breast Surgery, Training and Education

Chair: *Mr Dick Rainsbury and Mr Joe O'Donoghue*

10:00 to 10:15

NMBRA – 4th Annual Report

Mr Ranjeet Jeevan,
Clinical Effectiveness Unit, Royal College of Surgeons of England

10:15 to 10:30

NMBRA: Achievements and challenges

Mr Dick Rainsbury, Royal Hampshire County Hospital

10:30 to 10:45

Daycase / 23 hour breast surgery

Ms Angie Robinson,
National Improvement Lead NHS Improvement

10:45 to 11:00

MS in Oncoplastic Breast Surgery: Early Experience & Trainee Feedback

Prof Jerome Pereira,
James Paget University Hospital, Great Yarmouth

Charter 3 - 5

09:00 to 10:00
Session 11

Poster Presentation Session

Chairs: *Mr Lee Martin & Mr Stewart Nicholson*

Oral presentations of the best 12 posters

10:00 to 11:30
Session 13

Breast Cancer Audit Data

Chair: *Mr Neil Rothnie*

10:00 to 11:30

Analysis of Breast Cancer Audit Data

Dr Gill Lawrence,
West Midlands Cancer Intelligence Unit

External commentator:

Prof Michael Kerin

continued...

Tuesday 17th May 2011 continued

Exchange Auditorium

Oncoplastic Breast Surgery, Training and Education continued...

11:00 to 11:15

Subspecialisation and Training Update

Miss Fiona MacNeill,

Royal Marsden Hospital, London

11:15 to 11:30

Discussion

Charter 3 - 5

Breast Cancer Audit Data continued...

11:30 to 12:00 Tea & Coffee Break

12:00 to 12:30

Session 14

The National Cancer Intelligence Network

Chair: *Mr Neil Rothnie*

12:00 to 12:30

National Cancer Intelligence Network Update

Mrs Di Riley,

NCIN Clinical Outcomes Programme Manager

12:30 to 13:30

Session 16

Breast Cancer Research

Chair: *Mr Kieran Horgan*

12:30 to 12:50

The future design of research studies evaluating surgical treatments

Miss Zoe Winters, Bristol Royal Infirmary

12:50 to 13:10

Low Grade DCIS Trial Proposal

Miss Adele Francis,

Queen Elizabeth Hospital, Birmingham

13:10 to 13:30

POETIC Trial Update

Prof Ian Smith, Royal Marsden Hospital, London

12:00 to 13:30

Session 15

Mammary Fold Symposium

Chair: *Mr Will Al Sarakbi*

12:00 to 12:30

Surgical Training in Australia

Mr James Kollias,

Royal Adelaide Hospital

12:30 to 13:00

Breast Cancer Trials Update

Miss Julie Doughty,

Western Infirmary, Glasgow

13:00 to 13:30

Autologous Fat Transfer

Miss Millie Bello,

Nottingham University Hospital

13:30 to 14:30 Lunch

continued...

14:30 to 15:00
Session 17

British Journal of Surgery Lecture

Chair: *Miss Julie Doughty*

Current indications and assessment of response to neoadjuvant breast cancer treatment

Prof Monica Morrow, Memorial Sloan-Kettering Cancer Centre, New York, USA

15:00 to 16:30
Session 18

Neoadjuvant Treatment

Chair: *Miss Julie Doughty*

15:00 to 15:20

Neoadjuvant Her-2 Directed Therapy

Dr Luca Gianni,
National Cancer Institute, Milan, Italy

15:20 to 16:30

Neoadjuvant Case Discussions

Panel:

Prof Monica Morrow

Prof Michael Kerin

Miss Fiona MacNeill

Dr Luca Gianni

Prof Ian Smith

Dr Liz Mallon

Dr Emma Hurley

16:30 Close of Meeting

International Guest Speakers



Luca Gianni, MD

Luca Gianni, MD, is Director of the Department of Medical Oncology and Head of the Strategic Project of New Drug Development in Solid Tumors at the Ospedale San Raffele in Milan, Italy. He obtained his MD with honours from the State University of Milan, Italy in 1976; 5 years later he was board-certified in Internal Medicine.

For many years Professor Gianni has worked on new drug development in the field of oncology, and on the pharmacological characterization and clinical application of innovative drug therapies in medical oncology, with special emphasis on breast cancer. Since 1996, he has been coordinator of a European Cooperative Group conducting trials in women with operable breast cancer.

Professor Gianni receives research grants from public and private funds to conduct clinical and translational studies. He has authored more than 130 articles in peer-reviewed journals, including *Annals of Oncology*, *Journal of Clinical Oncology* and *Clinical Cancer Research* and sits on the editorial boards of many international oncology and pharmacology journals. Professor Gianni is a member of several scientific and medical societies including the American Association for Cancer Research, the American Society for Clinical Oncology and the European Society for Medical Oncology (ESMO). He is also Advisor and Expert for Research Applications to the Italian Ministry of University and Research. In 1997 he founded the Michelangelo Foundation for the Advancement of Science and Treatment in Oncology, and is Chairman of the International Board of the Michelangelo Foundation Breast Cancer Study Group.



Mr James Kollias

James Kollias is a Senior Consulting Surgeon at the Royal Adelaide Hospital and BreastScreenSA. He is the current Chairman of the RACS Breast Section, Founding President of the Breast Surgeons' Society of Australia and New Zealand (BreastSurgANZ), and Chairman of the National Breast Cancer Audit Steering Committee.

Mr Kollias is appointed as a Senior Lecturer with the Department of Surgery, University of Adelaide. He has served on a number of advisory committees for the National Breast and Ovarian Cancer Centre and has published over 70 manuscripts in scientific journals and book chapters.

His current interests include breast surgical training, audit and oncoplastic surgery.



Dr Sabine Linn

Sabine Linn received her medical degree (1991, cum laude) at the State University Leiden, The Netherlands, and her internal medicine board certification (2000) at the University Medical Center Utrecht, The Netherlands. She earned her PhD (1998) on the subject of multidrug resistance in solid tumours from the Free University of Amsterdam under supervision of Prof. Dr H.M. Pinedo. She was awarded a Dutch Cancer Society Research Fellowship in 2000 and developed two conditional knock-out mouse models, one for non-small cell lung cancer and one for small cell lung cancer, respectively, in close collaboration with Dr Ralph Meuwissen in the laboratory of Prof. Dr A.J. Berns at the Netherlands Cancer Institute, Amsterdam, The Netherlands.

From 2001 to 2002 she was a postdoc research fellow in the laboratories of Prof. Dr P.O. Brown, and Prof. Dr M. van de Rijn, at Stanford University Medical School, Stanford, CA, where she contributed to the development of a molecular classification for soft tissue sarcomas. Back at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital in Amsterdam, she earned her medical oncology certification (2002-2005) and became a senior staff member of the Division of Medical Oncology (2003).

Since 2005 she is also group leader at the Division of Molecular Biology at the Netherlands Cancer Institute where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity. For this purpose they use several genome-wide approaches and molecular techniques, in order to dissect the mechanisms that divide clinically well-defined cohorts of breast cancer patients into resistant and sensitive to a particular drug. To further develop the above mentioned research line Dr. Linn was awarded a Dutch Cancer Society Clinical Research Award in 2006. Since 2008 Dr. Linn is chair of the Working Group on (neo)adjuvant systemic therapy of the Dutch Breast Cancer Trialists' Group (BOOG). Dr. Linn has served as author or co-author of 63 peer-reviewed publications.

International Guest Speakers



Monica Morrow, MD

Monica Morrow, MD is chief of the Breast Surgery Service, Anne Burnett Windfohr Chair of Clinical Oncology, co-chief of the Breast Program at Memorial Sloan-Kettering Cancer Center, and Professor of Surgery at Weill Medical College of Cornell University. Prior to this she served as the G. Willing Pepper Chair in Cancer Research and the chairman of the Department of Surgical Oncology at Fox Chase Cancer Center. From 1993 to June 2004, she was Professor of Surgery at Northwestern University Medical School and director of the Lynn Sage Comprehensive Breast Program at Northwestern Memorial Hospital. From 1999 – 2001 she also served as director of the Cancer Department of the American College of Surgeons and executive director of the American Joint Committee on Cancer.

A native of Bucks County, Pennsylvania, Dr. Morrow received her BS degree Magna Cum Laude from the Pennsylvania State University in 1974 and her MD in 1976 from Jefferson Medical College. She did her surgical residency at the Medical Center Hospital of Vermont from 1976-1981, followed by 2 years of surgical oncology training at Memorial Sloan-Kettering Cancer Center in New York. Dr. Morrow is the recipient of the Outstanding Professional Woman Award from the State of Illinois Federation of Business and Professional Women, the Alpha Omega Alpha Outstanding Clinical Faculty Award from the University of Chicago, the Women Making a Difference Award for Medical Innovations from the State of Illinois, and the Speaking of Women's Health Foundation Award. She is a Distinguished Alumni of the Pennsylvania State University and a Distinguished Alumni of Jefferson Medical College. She was also named an Honorary Fellow of the Royal College of Physicians and Surgeons (Glasgow).

She is the editor of 3 breast cancer textbooks and has published more than 300 book chapters, manuscripts, and editorials. She has served on the Board of Directors of the American Society of Clinical Oncology and the Society of Surgical Oncology, and is currently the President Elect of the Society of Surgical Oncology. Her interests include the application of clinical trials data in practice, the evaluation of new technology related to local therapy of breast cancer and surgical decision making.

CHEMO? NO CHEMO?

Over 200,000 assays received from 60+ countries

The **Oncotype DX**[®] Breast Cancer Assay helps you find an answer

Oncotype DX helps clarify one of the most difficult treatment questions by providing an individualized Recurrence Score[®] result that assesses the benefit of chemotherapy and the likelihood of breast cancer recurrence.^{1,2}

Visit us at www.oncotypedx.com

For information on how to order Oncotype DX or to receive specimen transportation boxes, please contact Customer Service via email at: international@genomichealth.com

References: 1. Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.* 2006;24(23):3726-3734. 2. Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004;351(27):2817-2826.



Genomic Health, Oncotype DX and Recurrence Score[®] are registered trademarks of Genomic Health, Inc.
©2010 Genomic Health, Inc. All rights reserved. GHI706A 03/10

oncotypedx[®]
Breast Cancer Assay

General Information

Registration Desk

Registration will be open in the Charter Foyer at the following times:

Monday 16th May 2011: 07:45 to 18:30

Tuesday 17th May 2011: 08:30 to 16:45

Lunch and Refreshments

Lunch and refreshments will be served at the times listed in the programme.

All refreshments will be served in Charter 6, 7 & 8.

Trade Exhibition

The Trade Exhibition will run in Charter 6, 7 & 8 for the duration of the meeting.

Slide Checking

A slide checking room will be available in Exchange Room 1 for the duration of the conference. Would any speaker who needs to hand their presentation in please take it to this room on arrival.

Posters

The poster presentations will be displayed in Charter 1 for the duration of the meeting. Poster presenters should remove their posters at the end of the lunch break (2.30pm) on Tuesday 17th May 2011. Any posters left after this time may be removed and disposed of.

Cloakroom

A cloakroom and luggage store will be available in the Charter Foyer for the duration of the meeting.

Security

In the interests of security, delegates are required to wear their name badges at all times during the meeting.

ABS Annual Dinner

The ABS Annual Dinner will be held at the Midland Hotel (Peter Street, Manchester) on Monday 16th May 2011 at 7.30pm for 8pm. Dress is lounge suits. The dinner will be followed by a disco

CPD

This meeting has been awarded CPD points by the Association of Surgeons of Great Britain and Ireland as follows:

Monday 16th May 2011: 7 points

Tuesday 17th May 2011: 6 points

The meeting has been awarded 12 RCR CPD Category 1 credits by the Royal College of Radiologists.

All delegates should sign the register of attendance and certificates of attendance will be issued at the close of the meeting.

Trade Exhibition

The exhibition will contain the following stands:

Agendia BV
Allergan
Avail Medical
Bard Limited
BCCOM Project
Breakthrough Breast Cancer
Breast Cancer Care
Carl Zeiss Ltd
Clover Leaf Medical
Covidien
DAAX Ltd
Eurosurgical Ltd
FaHRAS
Genomic Health Inc
GlaxoSmithKline
IGEA
Independent Cancer Patients Voice

International Health Technology Ltd
Johnson & Johnson Medical Ltd – Ethicon Endo Surgery
– Breast Care
Leica Biosystems
Lifecell, a KCI Company
Mammary Fold
Medasun Ltd
Mentor Medical Systems
Novartis Oncology
QADOS
Roche
Sigmacon Surgical Systems
Sloane Project
Sysmex UK Ltd
Thuasne Thamert
Wisepress Medical Bookshop
Woman Zone Distribution Ltd

The Association of Breast Surgery would like to thank these companies for their support of the meeting.

This meeting is supported by educational grants from the Association of Breast Surgery's corporate sponsors:





Our quality. Your body. *Beautiful.*

We make our products to satisfy the highest standards. Yours. With over two decades of experience and a global reputation for quality and integrity, our unmatched manufacturing expertise, structural excellence and safety record speak for themselves.

Feel confident. Feel safe. Be beautiful.

We invest in excellence.



For more information,
please visit our website
www.mentormedical.co.uk



Minimally Invasive Breast Surgery

removed intact in seven seconds
local anaesthesia

AVAIL MEDICAL

intact@availmedical.com.
01827 288 883
The UK's leading RF medical device distributor

**Bournemouth International Centre
21st & 22nd May 2012**



**Further details will appear on
the website in due course:**

www.associationofbreastsurgery.org.uk

Abstract submission will be available on the website from September



Association of Breast Surgery
at The Royal College of Surgeons
35 – 43 Lincoln's Inn Fields
London WC2A 3PE

T 020 7869 6853
F 020 7404 6574
E office@absghi.org.uk
W www.associationofbreastsurgery.org.uk